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Abstract: Point mutations are the most common cause of inherited diseases. Bioinformatics tools
can help to predict the pathogenicity of mutations found during genetic screening, but they may
work less well in determining the effect of point mutations in non-coding regions. In silico analysis
of intronic variants can reveal their impact on the splicing process, but the consequence of a given
substitution is generally not predictable. The aim of this study was to functionally test five intronic
variants (MYBPC3-c.506-2A>C, MYBPC3-c.906-7G>T, MYBPC3-c.2308+3G>C, SCN5A-c.393-5C>A,
and ACTC1-c.617-7T>C) found in five patients affected by inherited cardiomyopathies in the attempt
to verify their pathogenic role. Analysis of the MYBPC3-c.506-2A>C mutation in mRNA from the
peripheral blood of one of the patients affected by hypertrophic cardiac myopathy revealed the loss
of the canonical splice site and the use of an alternative splicing site, which caused the loss of the
first seven nucleotides of exon 5 (MYBPC3-G169AfsX14). In the other four patients, we generated
minigene constructs and transfected them in HEK-293 cells. This minigene approach showed that
MYBPC3-c.2308+3G>C and SCN5A-c.393-5C>A altered pre-mRNA processing, thus resulting in the
skipping of one exon. No alterations were found in either MYBPC3-c.906-7G>T or ACTC1-c.617-7T>C.
In conclusion, functional in vitro analysis of the effects of potential splicing mutations can confirm or
otherwise the putative pathogenicity of non-coding mutations, and thus help to guide the patient's
clinical management and improve genetic counseling in affected families.
Keywords: minigene; splicing analysis; inherited cardiomyopathies; non-coding variations; intronic
mutations; SCN5A; MYBPC3; ACTC1
1. Introduction
Once a new mutation has been identified, the next step is to look for its pathogenicity, which may
be assessed at different confidence levels. According to the American College of Medical Genetics
and Genomics (ACMG), the most important criteria to establish causality of putative disease-causing
mutations are minor allele frequency (MAF), co-segregation, and in silico pathogenicity scores [1–3].
Co-segregation of a novel variant with disease within families is useful for variant classification, but
may be complicated by the structure of the pedigree, the issue of non-paternity, and by variable
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penetrance and expression of the disease. Several bioinformatics studies have been performed in
the attempt to understand the molecular effects of variations in coding regions and in the consensus
sequences of the 3′ and 5′ splice sites (3′ss and 5′ss) [4,5]. In general, no bioinformatics tool achieves
complete accuracy and the predicted results are sometimes inconsistent. Moreover, there may be
discordance between in silico predictions and in vitro or in vivo functional studies, possibly due to
features not considered in the in silico approach [4,6].
A reliable functional assay is generally the best means with which to characterize the biological
effect of variants. Ideally, when a genetic variation is located in intronic regions, the patient’s RNA
should be analyzed by RT-PCR to verify if the variant potentially involved in pre-mRNA maturation
does indeed affect splicing [7,8]. If mRNA cannot be obtained due to the lack of an appropriate tissue
sample, a minigene or ectopically expressed mRNA (e.g., cardiac mRNAs extracted from peripheral
blood) can be used to experimentally analyze the intronic variations [9–11]. In many instances minigene
splicing analysis proved to be a sensitive and specific system for the study of presumptive splice
mutations [12–14].
In this study, we evaluated the effect on the splicing mechanism of five different intronic variations,
found in three genes (SCN5A, MYBPC3, and ACTC1) of five patients/families, and probably implicated
in the triggering of two inherited cardiomyopathies: Brugada syndrome (BrS) and hypertrophic
cardiomyopathy (HCM). Using an integrated approach, we first used the ACMG criteria to establish the
pathogenic effects of these variants, and then evaluated their function by mRNA or minigene analysis.
2. Results
2.1. Clinical Molecular Genetics
In the context of a large genetic screening of about 400 patients from Southern Italy affected
by inherited cardiomyopathies associated to sudden death risk, we analyzed a panel of 20 genes
implicated in these disorders (Table 1).
Table 1. Panel of genes screened according to diagnostic suspicion.
Gene Protein Pathological Phenotype
MYH7 Myosin, heavy chain 7 HCM, DCM
MYBPC3 Myosin binding protein C HCM, DCM
TNNT2 Troponin T2, cardiac type HCM, DCM
TNNI3 Troponin I3, cardiac type HCM
TPM1 Tropomyosin 1 HCM
MYL2 Myosin, light polypeptide 2 HCM
MYL3 Myosin, light polypeptide 3 HCM
ACTC1 Actin, alpha, cardiac muscle 1 HCM
LMNA A/C Lamin A/C DCM
SCN5A Voltage-gated sodium channel α-subunit BrS, LQTS, DCM
KCNQ1 Voltage-gated potassium channel α-subunit LQTS
KCNH2 Voltage-gated potassium channel α-subunit LQTS
KNCE1 Potassium voltage-gated channel subfamily E member 1 (β subunit) LQTS
KCNE2 Potassium voltage-gated channel subfamily E member 2 (β subunit) LQTS
DSP Desmoplakin ARVC
PKP2 Plakophilin 2 ARVC
DSG2 Desmoglein 2 ARVC
DSC2 Desmocollin 2 ARVC
JUP Junction plakoglobin ARVC
RYR2 Ryanodine receptor 2 CPVT
HCM, Hypertrophic cardiomyopathy; DCM, Dilated cardiomyopathy; LQTS, Long QT syndrome; BrS, Brugada
syndrome; ARVC, Arrhythmogenic right ventricular cardiomyopathy; CPVT, Catecholaminergic polymorphic
ventricular tachycardia.
We found 136 different mutations, of which 11 intronic variants were in the region of splice
sites. We did not analyze non-coding variants already functionally characterized or intronic variants
affecting canonic splicing sites when we did not have the patient’s mRNA. Thus, we focused on five
non-coding variants found in five independent patients (affected by HCM or BrS) and located in three
genes: two novel variants in MYBPC3 (c.2308+3G>C) and ACTC1 (c.617-7T>C), and two known, but
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not functionally characterized, disease-associated variants, one in MYBPC3 (c.506-2A>C) and the other
in SCN5A (c.393-5C>A) [15]. Finally, we analyzed the known variant c.906-7G>T in the MYBPC3
gene, which had not been previously associated to the HCM phenotype. The five non-coding variants
were located in the intronic regions very close to acceptor or donor splicing sites, and were found to
be heterozygous. No other mutations in the coding regions of screened genes were found in these
patients. We first evaluated MAF. None of the five variants were listed in the dbSNP, ExAC, or EVS
databases [16–18], apart from SCN5A-c.393-5C>A and MYBPC3-c.906-7G>T, which are recorded in the
ExAC database with MAF 0.012% and 0.027%, respectively. Segregation analysis was possible only in
two families, but was not informative (Figure S1).
2.2. In Silico Analysis
To verify the potential role of the variants identified by genetic screening, we used Alamut Focus
version 0.9 (Interactive Biosoftware, Rouen, France). Alamut is a licensed software package available
from Interactive Biosoftware (www.interactive-biosoftware.com). To determine the robustness of our
in silico predictions, we compared the effect on the splicing process of 10 previously reported intron
mutations verified by in vitro/in vivo assay [19–24] with the outcome of our Alamut analysis, and
obtained similar results (Supplementary Table S1). The results obtained with this predictor software
for the novel intron variants are summarized in Table 2.
(1) MYBPC3-c.506-2A>C is located in the acceptor splice site of intron 4 of the MYBPC3 gene. All
five algorithms run by Alamut showed that MYBPC3-c.506-2A>C severely affected the splicing
process. In fact, it caused the loss of the natural acceptor splice site. It also resulted in a cryptic
splice site at position MYBPC3-c.513.
(2) MYBPC3-c.906-7G>T is located in intron 9 of the MYBPC3 gene. Four algorithms (Splice Site
Finder, MaxEnt, GeneSplicer and Human Site Finder) of the Alamut software predicted a small
increase in the efficiency of the splicing acceptor site.
(3) MYBPC3-c.2308+3G>C: this novel mutation is located in the donor splice site of intron 23 of the
MYBPC3 gene. Two algorithms (MaxEnt and NN Splice) of the Alamut software predicted a
consistent alteration with a strength reduction (above 50%) of the natural donor site. The other
three algorithms also predicted a donor site alteration, but the percentage of variation induced by
the mutation was less than 33% (SSF ≥ −7.1%, GeneSplicer ≥ −32.8%; HSF ≥ −8%). The effect
of this change was not predictable by Alamut.
(4) SCN5A-c.393-5C>A is located in intron 3 of the SCN5A gene. Two tools of the Alamut software
(SSF and HSF) predicted the creation of a novel acceptor site (score increase of more than 70%),
although the other three algorithms did not reveal any differences between wild type (WT) and
mutated sequences. No algorithm scored the wild-type consensus site.
(5) ACTC1-c.617-7T>C: this novel mutation is located in the polypyrimidine tract of the acceptor site
of intron 4 in the ACTC1 gene. Three algorithms (MaxEnt, GeneSplicer and HSF) predicted no
differences between WT and mutant; the other two revealed minimal differences.
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Table 2. Splicing analysis results obtained with five algorithms and the Alamut software.
Gene NucleotideVariation
cDNA
Position §
Splice Site
Finder (0–100)
Max Ent Scan
(0–16) NNSPLICE (0–1) Gene Splicer (0–15)
Human Splicing
Finder (0–100) Alamut Predicted Change
WT MUT WT MUT WT MUT WT MUT WT MUT
MYBPC3 c.506-2A>C
c.506 * 87.86 — 12.9 — 0.96 — 10.25 — 92.79 — Acceptor splice site: −100%
c.513 ** — 75.34 — 4.64 NE NE — 3.65 77.42 79.45
MYBPC3 c.906-7G>T c.906 * 73.61 78.66 3.82 4.44 NE NE __ 2.29 80.55 82.75 Acceptor splice site: +223%
MYBPC3 c.2308+3G>C c.2308 * 77.58 72.06 8.99 3.77 0.87 — 12.67 8.52 85.13 78.32 Donor splice site: −52%
ACTC1 c.617-7T>C c.617 * 84.72 83.21 6.55 6.71 0.92 0.83 8.24 8.54 83.31 83.73 Acceptor splice site: −2%
SCN5A c.393-5C>A c.393-3 — 70.16 — 0.85 NE NE NE NE — 77.83 Acceptor splice site: 0%
Parentheses show the score range for each algorithm; —, splice site not detected; NE, splice site not evaluated by the algorithm; WT: wild type sequence; MUT: mutated sequence;
NNSPLICE: Neural Network Splice ; § first nucleotide of the splice site; * natural splice site; ** cryptic splice site.
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2.3. In Vitro Analysis
MYBPC3-c.506-2A>C. The RNA of an HCM patient carrying mutation MYBPC3-c.506-2A>C was
extracted from peripheral blood and was retrotranscribed by RT-PCR. The region spanning from exon 3
to exon 6 of MYBPC3 was amplified by specific primers. The MYBPC3-c.506-2A>C mutation causes
the complete loss of the canonic acceptor splicing site and the activation of a cryptic 3′ splice site at
position c.513, that induces the loss of seven nucleotides of exon 5. This RNA alteration results in the
substitution of glycine 169 with an alanine and a subsequent frame-shift and generation of a premature
stop codon (MYBPC3-G169AfsX14). The patient, who carried the mutation in a heterozygous pattern,
showed both a normal and an aberrant transcript (Figure 1).
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process in subjects with and without the MYBPC3‐c.506‐2A>C mutation. The red arrow represents 
the position of the mutation, the red box represents the deletion of seven nucleotides occurring in 
exon 5 of MYBPC3; (C) Electropherograms obtained from DNA sequencing of the fragments shown 
in panel A and relative splicing results (Black, red, green and blue peaks represent the G, T, A, and C 
bases, respectively). Deletion of seven nucleotides is represented by a red box. The blue line in the 
electropherograms indicates the end of exon 4 of MYBPC3 cDNA. 
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c.906‐7G>T or ACTC1‐c.617‐7T>C, nor the RNA of a BrS patient carrying the SCN5A‐c.393‐5C>A 
mutation was available, we used a minigene system to verify the results obtained with the Alamut 
predictor software. 
MYBPC3‐c.2308+3G>C. The analysis of the RNA obtained from the minigene system showed the 
generation of two transcripts (normal and alternative) in pMGene‐MYBPC3‐WT and only one 
(alternative) in pMGene‐MYBPC3‐c.2308+3G>C (Figure 2). 
Figure 1. Effect of the MYBPC3-c.506-2A>C mutation on the splicing mechanism. (A) Electrophoresis
of the RT-PCR analysis of mRNA extracted from the peripheral blood of a patient carrying the
YBPC3-c.506-2A>C mutation. Lane 1: Marker IX (Roche Diagnostics); Lane 2: Control; Lane 3:
Patient carrying the YBPC3-c.506-2A>C utation; (B) Sche atic representation of the splicing
process in subjects ith and ithout the YBPC3-c.506-2 >C utation. The red arro represents
the position of the utation, the red box represents the deletion of seven nucleotides occurring in
exon 5 of YBPC3; ( ) Electropherogra s obtained fro sequencing of the frag ents sho n
in anel an relative splicing results (Black, red, green and blue peaks represent the G, T, A, and
C bases, respectively). Deletion of seve nucleotides is represented by a red box. The l e li e i t e
electr er r s i ic tes t e e f e f c .
Since neither the RNA of HCM patients carrying mutation MYBPC3-c.2308+3G>C,
MYBPC3-c.906-7G>T or ACTC1-c.617-7T>C, nor the RNA of a BrS patient carrying the
SCN5A-c.393-5C>A mutation was available, we used a minigene system to verify the results obtained
with the Alamut predictor software.
MYBPC3-c.2308+3G>C. The analysis of the RNA obtained from the minigene system showed
the generation of two transcripts (normal and alternative) in pMGene-MYBPC3-WT and only one
(alternative) in pMGene-MYBPC3-c.2308+3G>C (Figure 2).
Int. J. Mol. Sci. 2016, 17, 1883 6 of 13
Int. J. Mol. Sci. 2016, 17, 1883 6 of 13 
 
 
Figure 2. Effect of the MYBPC3‐c.2308+3G>C mutation on the splicing mechanism. (A) Schematic 
representation of the pMGene empty vector. The GFP coding sequence (green box) is fused with exon 
1 of the human β‐globin. The exons of human β‐globin are shown in blue boxes. The red arrow shows 
the position of the KpnI restriction site where the insert, containing the exon and the 5′ and 3′ intronic 
flanking regions, was cloned. The black arrows indicate the primers used for PCR analysis; (B) 
Schematic representation of the splicing process in pMGene‐MYBPC3 constructs (WT, upside; 
mutated, downside). The red arrow indicates the position of the mutation. The blue boxes represent 
the exons of human β‐globin, the red box represents the MYBPC3‐exon 23 cloned in the pMGene 
vector; (C) Electrophoresis of the RT‐PCR analysis of mRNA extracted from cell lines transfected with 
pMGene‐MYBPC3 (WT or mutated). Lane 1: Marker VI (Roche Diagnostics); Lane 2: pMGene‐
MYPC3‐WT; Lane 3: mutated pMGene‐MYBPC3; (D) Electropherograms obtained from the DNA 
sequencing of fragments a, b, and c (right) extrapolated from panel B and relative splicing results 
(Black, red, green and blue peaks represent the G, T, A, and C bases, respectively). The blue line in 
the electropherograms shows the end of exon 2 of β‐globin. 
The alternative transcript, obtained by minigene assay, arose from the skipping of the MYBPC3 
gene exon 23, which hypothetically is also present in the RNA of the patient, but where possible direct 
analysis should be performed (Figure 2). This alteration causes the substitution of leucine 717 with a 
threonine, and premature generation of a stop codon after 51 codons (MYBPC3‐L717TfsX51). 
ACTC1‐c.617‐7T>C and MYBPC3‐c.906‐7G>T. No RNA alterations were found in the mutated 
ACTC1 (Figure 3) or in MYBPC3 minigenes compared with the WT. 
Figure 2. Effect of the MYBPC3-c.2308+3G>C utation on the splicing mechanis . (A) Sche atic
representation of the p Gene empty vector. The GFP coding sequence (green box) is fused with
exon 1 of the human β-globin. The exons of human β-globin are shown in blue boxes. The red
arrow shows the position of the KpnI restriction site where the insert, containing the exon and the
5′ and 3′ intro ic flanking regions, was cloned. The black arrows indicate the primers used for
PCR analysis; (B) Schematic representation of the splicing process in pMGene-MYBPC3 constructs
(WT, upsi e; mutated, downside). The red arrow indicates the position of t m tation. The blue
boxes represent the exons of human β-gl bin, th red box represents the MYBPC3-exo 23 cloned in
th pMGene vector; (C) Electrophoresis of the RT-PCR analysis of mRNA extracted from ell lines
transf cted with pMGene-MYBPC3 (WT or mutated). Lane 1: Marker VI (R che Diag ostics); Lane 2:
pMGene-MYPC3-WT; Lane 3: mutated p Gene-MYBPC3; (D) Electropherograms obtained from the
DNA sequencing of fragments a, b, and c (right) extrapolated from panel B and relati e res lts
(Black, red, gre n and blue peaks repres nt the G, T A, and C bases, resp ctively). The blue ine i the
electropherograms shows the end of ex n 2 f β-globin.
The alternative transcript, obtained by minigene assay, arose from the skipping of the MYBPC3
gene exon 23, which hypothetically is also present in the RNA of the patient, but where possible direct
analysis should be performed (Figure 2). This alteration causes the substitution of leucine 717 with a
threonine, and premature generation of a stop codon after 51 codons (MYBPC3-L717TfsX51).
ACTC1-c.617-7T>C and MYBPC3-c.906-7G>T. No RNA alterations were found in the mutated
ACTC1 (Figure 3) or in MYBPC3 minigenes compared with the WT.
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SCN5A-c.393-5C>A. The analysis of the RNA obtained from the minigene system showed the
generation of an alternative transcript in pMGene-SCN5A-c.393-5C>A generated from the skipping
of exon 4, which hypothetically is also present in the RNA of the patient. The normal transcript
was obtained from the pMGene-SCN5A-WT (Figure 4). The skipping of exon 4 causes the in-frame
deletion of 30 amino acids in the protein (Nav1.5-L132_E161del). The deletion is located in the S1
transmembrane segment of the DI domain [25].
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3. Discussion 
RNA splicing is the process during which the correct recognition of splicing sequences enables 
intron removal and exon joining. Variations affecting splicing sites impair this process and produce 
a sizeable percentage of genetic diseases. About 10% of disease‐causing mutations annotated in the 
Human Gene Mutation Database [26] are intronic variations that give rise to mRNA splicing. Intron 
variants play a crucial role in the etiology of inherited cardiac conditions including cardiomyopathies 
and ion channelopathies. In this setting, genetic cascade testing is recommended after the initial 
identification of a pathogenic variation in order to identify asymptomatic relatives who might be at 
risk of disease‐related complications, mainly the risk of sudden cardiac death [27]. Therefore, the 
identification of a causal variant is essential for a correct diagnosis and to plan other pre‐symptomatic 
clinical decisions. Notably, the Association for Clinical Genetic Science does not recommend 
predictive testing for a variant of uncertain significant (VUS) for other family members [28]. 
In this study, we analyzed the pathogenic effect of five intronic variants (MYBPC3‐c.506‐2A>C, 
MYBPC3‐c.906‐7G>T, MYBPC3‐c.2308+3G>C, SCN5A‐c.393‐5C>A, and ACTC1‐c.617‐7T>C) that may 
affect the splicing process. We found these variants in the setting of genetic testing for cardiomyopathies, 
which involved the analysis of 20 genes (coding regions and their flanking portions), selected on the 
basis of clinical suspicion. Splicing mutations accounted for 8.1% of all mutations detected, which is 
comparable to the percentage of splicing mutations annotated in the Human Gene Mutation Database 
[26]. Apart from MYBPC3‐c.906‐7G>T and SCN5A‐c.393‐5C>A, no variant was recorded in the 
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Figure 4. Effect of the SCN5A-c.393-5C>A mutation on the splicing mechanism. (A) Schematic
representation of the splicing process in pMGene-SCN5A constructs (WT, upside; mutated, downside).
The red arrow shows the position of the mutation. The blue boxes represent the exons of human
β-globin, the red box represents the SCN5A-exon 4 cloned in the pMGene vector. The black arrows
indicate the primers used for PCR analysis; (B) RT-PCR analysis of mRNA extracted from cell lines
transfected with pMGene-SCN5A (WT or mutated). Lane 1: pMGene-SCN5A-WT; Lane 2: mutated
pMGene-SCN5A; Lane 3: Marker VI (Roche Diagnostics); (C) Electropherograms obtained from DNA
sequencing of the fragments shown in panel B and relative splicing results (Black, red, green and blue
peaks represent the G, T, A, and C bases, respectively). The blue lines in the electropherograms show
the end of exon 2 of β-globin.
3. Discussion
RNA splicing is the process during which the correct recognition of splicing sequences enables
intron removal and ex n joining. Variations affecting splicing sites impair this process and produce
a size ble percentage of genetic diseases. About 10% of disease-causing mutations annotated i the
Human Gene Mutation Database [26] are intronic variations that give rise to mRNA splicing. Intron
variants play a crucial role in the etiology of inherited car iac co ditions includi g cardiomyopathies
and ion cha nelopathies. In this setting, genetic cascade testing is recommended after the initial
identification of a pathogenic v riation in order to identify asymptomatic rel tives who might be at
risk of disease-related complications, mainly the risk of sudden cardiac death [27]. Therefore, the
ide tification of a causal variant is essenti l for a correct di gnosis and to plan oth r pre-sympto atic
clinical decisions. N tably, the Association for Clinic l Genetic Science does not recommend predictive
testing for a variant of u certain significant (VUS) for ther family members [28].
In this study, we analyzed the pathogenic effect of five intronic variants (MYBPC3-c.506-2A>C,
MYBPC3-c.906-7G>T, MYBPC3-c.2308+3G>C, SCN5A-c.393-5C>A, and ACTC1-c.617-7T>C) that
may affect the splici g process. W found these variants in the setting of genetic testing for
cardiomyopathies, which involved the analysis of 20 genes (coding regions and their flanking portions),
selected on the basis of clinical uspicion. Splicing mut tions accounted for 8.1% of all mutations
detected, which is comparable to the perce tage of splicing mutatio s annotated in th Human Gene
Mutation Database [26]. Apart from MYBPC3-c.906-7G>T and SCN5A-c.393-5C>A, no variant was
recorded in the dbSNP, ExAC, or EVS databases [16–18]. Variant YBPC3-c.906-7G>T was identified
in a atient affected by HCM; it is pr sent in the ExA database showing a MAF of 0.027%, which
i just above the prev lence of HCM (0.02%). The SCN5A-c.393-5C>A variant was i entified in a
patient with suspected BrS: it had a MAF of 0.012%, w ich is lower than the allowable estimated
disorder allele frequency (prevalence of BrS: 0.05% [29]). Variants with an MAF below cutoff, based
on disord r frequency and inh ritance pattern, are most likely to be pat ogenic [3]. Based on MAF
criteria, four of the five intronic variants are pathogenic. Co-segregation analysis of the variant and the
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disorder within families was possible only for MYBPC3-c.506-2A>C and SCN5A-c.393-5C>A, but the
number of informative meioses within the pedigrees was not sufficient to establish pathogenicity [28].
However, these two variants co-occurred with the disorder (HCM and BrS, respectively) in previous
reports [15,30].
Verification of a potential disease-related mutation is performed using in silico procedures
and in vitro functional analysis. Notably, results are obtained sooner with the former procedure,
whereas in vitro functional analysis can be performed only in well-equipped laboratories. In our
study, the mutation disrupting the canonical AG/GT dinucleotides (MYBPC3-c.506-2A>C) resulted in
a splice defect due to the loss of a canonical site and the use of a cryptic acceptor site 7 nucleotides
downstream. In the case of this variant, there was a 100% concordance between the in silico prediction,
which highlighted the activation of a cryptic 3′ splice site, and the results of the RNA analysis of
the patient’s blood. Bioinformatics analysis of MYBPC3-c.2308+3G>C revealed that the score of the
canonical donor splice site was decreased using all five bioinformatics tools, and the decrease exceeded
50% with two tools. Accordingly, minigene analysis of the mutated construct revealed skipping of
MYBPC3 exon 23. However, HEK293 cells transfected with the WT minigene showed the coexistence
of normal and skipped transcripts, therefore suggesting that the canonical 5′ss of intron 23 is weak and
is not always recognized in HEK293 cells.
In silico analysis of SCN5A-c.393-5C>A showed a de novo creation of an acceptor site 3 nucleotides
upstream the canonical site, whereas the minigene approach revealed skipping of SCN5A exon 4.
In this case, the creation of a de novo 3′ss, suggested by the in silico analysis, did not correspond to the
splicing alteration that occurred in vitro, which is consistent with exon skipping. Of note, the wild-type
consensus site was not scored. The better the definition of the consensus site, the more reliable the
predictions. If the wild-type consensus site is poorly defined or not defined, the bioinformatics
predictions may not reflect the alternative situation. Bioinformatics tools, as well as in vitro analysis
conducted with the minigene approach, did not show altered RNA splicing in the presence of variants
MYBPC3-c.906-7G>T and ACTC1-c.617-7T>C.
Splicing alterations elicited by the MYBPC3-c.506-2A>C and MYBPC3-c.2308+3G>C mutations
produced a frame-shift that translates in the loss of function of the mutated allele, possibly due to
nonsense-mediated decay or C-terminal truncations; this pathogenetic mechanism is in agreement
with the main pathogenic mechanism by which MYBPC3 mutations act, i.e., the haploinsufficiency.
The skipping of exon 4 produced by SCN5A-c.393-5C>A causes the in-frame deletion of 30 amino acids
in the S1-DI transmembrane segment of the cardiac sodium channel alpha-subunit. In each domain,
the S1–S3 segments strongly interact with the S4 segment to form the voltage-sensor domain [25,31].
It is plausible that the lack of 30 amino acids in the S1-DI segment leads to loss of function of the
cardiac sodium channel, which is compatible with BrS symptoms. Therefore, our results also shed
light on the molecular basis and the likely pathogenic mechanism in two HCM patients/families and
in one BrS patient/family.
Finally, the procedure described herein identified three disease-causing mutations out of
the five evaluated. Consequently, the three affected families are candidates for cascade genetic
screening to identify asymptomatic carriers in the families, who can then be enrolled in treatment or
monitoring programs.
4. Materials and Methods
4.1. Molecular Genetics
Genomic DNA was isolated from peripheral whole blood with the Nucleon BACC2 kit (GE
Healthcare, Life Sciences, Little Chalfont Buckinghamshire, UK). All coding exons, and 5′ and 3′ UTRs
of genes involved in inherited cardiomyopathies associated to sudden death were amplified by PCR
and analyzed by automatic sequencing using previously reported protocols [32]. Based on diagnostic
suspicion, patients were screened for a specific gene panel (Table 1). In some patients, we analyzed a
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large number of target genes using Next Generation Sequencing methodology and the variant selection
criteria reported previously [33]. Informed consent to perform genetic analysis was obtained from
patients according to the second Helsinki Declaration [34]. Genetic analysis was extended to relatives
when possible to verify segregation of a putative mutation with disease in the family.
4.2. Splice-Site Prediction Analysis
Alamut software was used for in silico prediction of splice-affecting nucleotide variants. Genomic
sequences (WT and mutant) were processed by this predictor software using five splicing prediction
tools (SpliceSiteFinder-like, MaxEntScan, Neural Network Splice, GeneSplicer, and Human Splicing
Finder). Each tool is based on different algorithms: SpliceSiteFinder-like uses position weight matrices
computed from a set of human constitutive exon/intron junctions for donor and acceptor sites;
MaxEntScan and NNPLICE are based on the Maximum Entropy principle and neural networks,
respectively. GeneSplicer combines several splice site detection techniques, namely Markov models;
and HSF is based on position weight matrices with some position-dependent logic [35].
4.3. In Vitro RNA Splicing Analysis of MYBPC3-c.506-2A>C
Total RNA was directly extracted from 5 mL of patients’ peripheral blood by Trizol Reagent
(Thermo Fischer Scientific, Waltham, MA, USA). RNA retro-transcription was performed as previously
described [9], using specific primers spanning from exon 3 to exon 6. Forward primer was drafted
to overlap between exon 3 and 4 of the MYBPC3 transcript (Forward, 5′-CAAGTCCCAAAGGG
TCAAGCTC-3′ and Reverse, 5′-GTGGACACCTCACAGCGGTA-3′).
4.4. In Vitro RNA Splicing Analysis by Minigene
4.4.1. Insert Generation (MYBPC3-c.906-7G>T, MYBPC3-c.2308+3G>C, SCN5A-c.393-5C>A,
ACTC1-c.617-7T>C)
The genomic regions affected by non-coding mutations were amplified by PCR using PCR Master
Mix (Promega, Madison, WI, USA). The PCR amplicons contained both the interested exon (the region
including exon 9-10-11 of MYBPC3 gene; exon 23-MYBPC3; exon 4-SCN5A; the region spanning from
exon 4 to exon 5-ACTC1) and the 5′ and 3′ intronic flanking regions. The primers contained a KpnI
restriction sequence at the 5′ terminus. The primers used for PCR are listed in Supplementary data
(Table S2). The sizes of inserts obtained by PCR were approximately 1000 base pairs.
4.4.2. Minigene Plasmid Construction, Expression, and Transcripts Analysis
The PCR fragments obtained by PCR were cloned into the pMGene vector [11]. The empty vector
contained the human β-globin gene, from the starting codon to the stop codon (including introns), and
the GFP coding sequence fused with exon 1. A unique KpnI restriction site was located in the middle
of β-globin intron 2 (Figure 2A). PCR products and the pMGgene vector were digested by the KpnI
restriction enzyme. The open pMGene vector was then dephosphorylated. The digested inserts were
then cloned into the pMGene vector using the LigaFast Rapid DNA Ligation System (Promega). All
clones were sequenced, and the WT and mutated forms of each construct (pMG-MYBPC3, pMG-ACTC1,
and pMG-SCN5A) were selected for expression experiments.
HEK-293 cells were grown in Dulbecco’s modified eagle medium supplemented with 10%
FBS, 2 mM L-glutamine and 1% penicillin/streptomycin in a humidified, 5% CO2 atmosphere at
37 ◦C. Cells were transiently transfected with 2 µg of WT or mutated pMGene using FuGene HD
(Promega). Forty-eight hours after transfection, cells were collected and RNA was extracted by
Trizol Reagent (Life Technologies). RNA retrotranscription was performed by SuperScript VILO (Life
Technologies) starting from 1 µg of total RNA and using random primers. The cDNA obtained was
amplified with the following primers: forward, 5′-ACGACGGCAACTACAAGACC-3′ and reverse,
5′-CACACCAGCCACCACTTTC-3′ annealing in the GFP-coding region and in exon 3 of β-globin,
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respectively (Figure 2A). Since the forward primer annealed in the GFP-coding region, only located
in the transcripts derived from the plasmid construct, the PCR did not select endogenous β-globin,
MYBPC3, ACTC1, or SCN5A transcripts.
5. Conclusions
This study illustrates the efficacy of an integrated approach, constituted by indirect criteria (MAF,
co-segregation, and co-occurrence), in silico simulation and RNA analysis (directly or with minigene
technology) to determine the effect of potential splice site variants. Bioinformatics can be used to
filter more likely disease-causing variants from among the large number of candidates detected by
high-throughput DNA sequencing. Subsequently, in silico predictions, particularly when obtained by
the evaluation of multiple algorithms, can be verified in vitro. Notably, the RNA analysis performed
by RT-PCR of the patient’s RNA or by the minigene approach should invariably be used whenever
possible to reach a reliable conclusion concerning pathogenicity.
In conclusion, we identified the molecular basis and the likely pathogenic mechanism in two HCM
patients/families and in one BrS patient/family. These findings can improve the genetic counselling of
patients and their relatives.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/17/11/1883/s1.
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